Product image of Limoda (Fingolimod) supplied by GNH India

Limoda

Active Ingredient:
Fingolimod
Origin:
EU

Limoda (Fingolimod)

Fingolimod, the active ingredient in Limoda, is a sphingosine‑1‑phosphate (S1P) receptor modulator presented as an oral tablet for oral administration. It is used as a disease‑modifying therapy for relapsing‑remitting multiple sclerosis in adult patients, helping to reduce the frequency of clinical relapses and delay disability progression.

GNH India supplies Limoda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union regulatory standards and is manufactured under GMP conditions. It is distributed through a secure cold‑chain logistics network to ensure product integrity.

Manufacturer / TM Owner

Mensana Pharma Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Limoda (fingolimod) is an oral disease‑modifying therapy that targets sphingosine‑1‑phosphate receptors to manage multiple sclerosis.
  • Relapsing‑remitting multiple sclerosis: reduces annualized relapse rate and slows disability progression.
  • Maintenance therapy in RRMS: provides long‑term control of disease activity.
  • MRI disease activity: decreases the number of new or enlarging T2 lesions.

How It Works

  • Fingolimod is phosphorylated in vivo to an active metabolite that selectively binds to sphingosine‑1‑phosphate receptor subtypes 1, 3, 4 and 5. This binding causes internalisation of the receptor on lymphocytes, preventing their egress from lymph nodes and thereby reducing the migration of autoreactive lymphocytes into the central nervous system, which diminishes inflammatory demyelination.

Side Effects

Common Side Effects

  • Headache: mild to moderate intensity.
  • Nasopharyngitis: upper respiratory tract infection symptoms.
  • Diarrhoea: occasional loose stools.
  • Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects

  • Infections: opportunistic or severe bacterial infections.
  • Cardiac arrhythmia: bradycardia or atrioventricular block.
  • Macular oedema: visual disturbances requiring ophthalmologic evaluation.
  • Progressive multifocal leukoencephalopathy: rare but potentially fatal viral infection.
  • Severe liver injury: marked hepatic enzyme elevation or hepatitis.

Precautions & Warnings

Before initiating therapy, clinicians should assess baseline cardiac function and liver enzymes, and review vaccination history.

  • Cardiac monitoring: obtain baseline ECG and observe for bradycardia after first dose.
  • Liver function: check ALT/AST before start and periodically during treatment.
  • Vaccination status: avoid live vaccines while on therapy.
  • Pregnancy and lactation: discuss potential risks; use only if benefit outweighs risk.
  • Concomitant immunosuppression: evaluate infection risk before combining with other immunosuppressants.

Store at room temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Fingolimod may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase fingolimod exposure.
  • Live vaccines: risk of disseminated infection.
  • Drugs causing bradycardia (e.g., beta‑blockers): may exacerbate heart‑rate slowing.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise plasma levels.

  • Antihypertensive agents: monitor blood pressure for additive effects.
  • Other immunosuppressants (e.g., azathioprine): increased infection risk.

Frequently Asked Questions

Limoda contains fingolimod, an oral sphingosine‑1‑phosphate receptor modulator indicated as a disease‑modifying therapy for relapsing‑remitting multiple sclerosis in adult patients. It helps lower the frequency of clinical relapses and may slow the progression of disability associated with the disease.

Fingolimod is phosphorylated after ingestion to an active metabolite that binds selectively to S1P receptor subtypes on lymphocytes. This binding causes receptor internalisation, trapping lymphocytes in lymph nodes and preventing them from entering the central nervous system, thereby reducing inflammatory activity that drives multiple sclerosis lesions.

The prescribed dose of Limoda is determined by the treating physician based on the patient’s clinical condition, renal function, and other individual factors. Only a qualified healthcare professional can set the appropriate dosing regimen for each patient.

The safety of fingolimod in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescribing clinician in consultation with the patient.

To request Limoda, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Limoda (fingolimod) is an oral S1P‑receptor modulator, offering a convenient once‑daily tablet compared with injectable or infusion‑based disease‑modifying therapies. Its efficacy in reducing relapse rates is comparable to some high‑efficacy agents, but safety profiles differ, particularly regarding cardiac and infection risks.

Limoda should be stored at room temperature below 25 °C, in its original blister pack, protected from moisture and direct sunlight. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Limoda is taken orally as a tablet, usually once daily with or without food, as directed by the prescribing physician. Patients should swallow the tablet whole and follow any specific instructions provided by their healthcare provider.

Serious risks include cardiac events such as bradycardia or atrioventricular block, severe infections (including opportunistic pathogens), macular oedema affecting vision, and rare but serious liver injury. Patients should be monitored regularly for these adverse events.

Limoda is contraindicated in patients with known hypersensitivity to fingolimod or any of its excipients, those with recent myocardial infarction, unstable angina, stroke, or uncontrolled cardiac disease, and individuals with severe hepatic impairment. A thorough medical assessment is required before initiation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fingolimod

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT